This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The World Market For Stents (Drug-Eluting And Bare Metal Product Markets In US, EU, Japan, India, China And ROW)

 

 

 

NEW YORK, Nov. 8, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The World Market for Stents (Drug-Eluting and Bare Metal Product Markets in US, EU, Japan, India, China and ROW)

http://www.reportlinker.com/p01025631/The-World-Market-for-Stents-Drug-Eluting-and-Bare-Metal-Product-Markets-in-US-EU-Japan-India-China-and-ROW.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices

The coronary stents industry is a highly competitive one in which innovation occurs rapidly and the technology landscape evolves at a fast pace. As the global population is aging and has a longer life expectancy, the prevalence of coronary heart disease and co-morbid conditions such as hypertension, diabetes and obesity is projected to rise and stimulate the demand for coronary stents. Additionally, a growing acceptance of drug-eluting stents as a more effective treatment for coronary heart disease, along with increasing awareness about coronary stents among patients, is expected to boost procedural volumes. New technologies, such as bioresorbable scaffolds, and bifurcation and biodegradable polymers stents, are projected to enter major markets in the next years and increase the utilization of stents in interventional cardiology.

Despite the challenging environment, opportunities still exist in the global market for coronary stents, as there is still a high need for non-invasive therapies with enhanced safety and efficacy, and there are various niches of the market, such as bifurcation and complex lesions, that require more extensive treatment options. Additionally, the new bioresorbable stents have the potential to eliminate the negative issues of durable polymer stents, and are therefore expected to induce a significant shift in the treatment of coronary heart disease, encouraging also more patients to undergo stent implantation surgery.

This Report, The World Market for Stents (Drug Eluting and Bare Metal Product Markets in U.S., E.U., Japan, China, India and ROW) provides a complete overview of cardiovascular disease, the role of stents in treatment, the success of bare metal and drug-eluting products, as well as market sizes and forecasts to 2017. Included in this reports coverage:

Market Size and Forecast -Cardiovascular Disease Statistics (Mortality, Morbidity, Cost by Country)

  • Regional Breakout of Bare Metal and Drug-Eluting Stent Markets (U.S., E.U., Japan, China, India, ROW)
  • Categorization of Drug-Eluting Stents by Polymer, Drug, Platform
  • Coronary Stents Using Biodegradable Polymers, Novel Coating and Direct Drug Application
  • Assessment of Bioresorbable Stents
  • Dedicated Bifurcation, Dedicated Small Vessel Stent Products
  • Major Competitors Market Share
  • Significant Trends in Market and Near and Long-Term Impact
  • Recent Mergers and Acquisitions
  • Key Company Profiles

The major markets of US, Europe, and Japan experienced significant challenges in recent years, including price declines, decreasing volumes of percutaneous coronary interventions, and lower penetration rates for drug-eluting stents resulted from cost constraints and reductions in healthcare budgets. Additionally, the intensified competition among manufacturers also contributed to the decline in average stent selling prices in these regions. Despite that, the market potential for coronary stents in these regions remains quite attractive, given the aging population and high longevity. However, the decreasing reimbursement rates and the intensifying competition for market share are expected to continue to lead to price declines and hamper significantly the market growth.

As part of its coverage of the stents industry, the following companies are profiled:

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs